GlobeNewswire

MIMEDX Announces Publication in the Journal of Inflammation Focused on Immunomodulatory Effects of Purion® Processed Human Amniotic Membrane Allografts In Vitro
19/12/2025
Study investigates the influence of MIMEDX DHACM and LHACM products on inflammatory response, which supports the healing cascade and tissue repair MARIETTA, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. ( [...]
Remedy's Nutrition® Launches Mega VMT™ High-Potency Multivitamin to Revolutionize Daily Energy and Nutritional Wellness
19/12/2025
KEY LARGO, Fla., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Remedy's Nutrition®, a trusted natural dietary supplement company since 1972 and a leader in premium herbal formulations, today announced the strategic expansion of its [...]
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
19/12/2025
TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids [...]
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
19/12/2025
Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) [...]
Amplia Enters into Second Agreement with Korean Specialist Drug Screening Company Next&Bio to Explore Combination Therapy with FAK Inhibitor and kRAS Inhibitors
19/12/2025
HIGHLIGHTS The preclinical research collaboration with specialist drug screening company Next & Bio has been extended The collaboration explores the effect of Amplia’s FAK inhibitors in combination with experimental [...]
NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary, Good Salt Life, Inc., Launches Brands PurrGuard® and Dog Gone Odor®, EPA-registered Odor-killing Bacteria Chemistry for Companion Animals
19/12/2025
ATHENS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NDT Pharmaceuticals, Inc.’s (OTC: NDTP) wholly-owned subsidiary Good Salt Life, Inc. , a pioneer in innovative surface treatment and biosecurity solutions, announces a [...]
Sienna Completes Acquisition in the Greater Toronto Area
19/12/2025
This news release constitutes a “designated news release” for the purposes of Sienna’s amended and restated prospectus supplement dated November 14, 2025 to its short form base shelf prospectus dated November 29, 2024. [...]
Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses
19/12/2025
The PL-16 Viral Blocker has shown over 90% success in protection of cells against viruses Raanana, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd., a pre-clinical-stage biotechnology company developing [...]
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
19/12/2025
ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Mesa Labs to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
19/12/2025
LAKEWOOD, Colo., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced that [...]
Nxera Pharma to Regain Full Rights to GPR52 Agonist Program for Schizophrenia
19/12/2025
Tokyo, Japan and Cambridge, UK, 19 December 2025 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces that Boehringer Ingelheim has informed the Company of its decision not to exercise its [...]
Senti Biosciences Announces New Employment Inducement Grants
18/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its [...]
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients
18/12/2025
Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“ [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/12/2025
FOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock options to [...]
Crescent Biopharma Announces Grants of Inducement Awards
18/12/2025
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer [...]
AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
18/12/2025
VALENCIA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, [...]
vTv Therapeutics and M42’s IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
18/12/2025
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
18/12/2025
CONSHOHOCKEN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
18/12/2025
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 44 th [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum